Tenet Medicines to Be Acquired by Eliem Therapeutics

Boston – April 11, 2024 – Cooley advised Tenet Medicines, a development-stage private biotechnology company, on its definitive agreement to be acquired by Eliem Therapeutics (Nasdaq: ELYM), a biotech company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The acquisition is expected to close in the middle of 2024, subject to Eliem stockholder approval – including approval by holders of a majority of outstanding shares not held by affiliates of RA Capital Management – and other customary closing conditions.

Lawyers Elizabeth Galvin, Miguel Vega, Eric Blanchard, Ryan Sansom, Mike Nelson, Kurtis Zinger, Chelsea Braun, Margaux Arntson, Katrina Morris, Stephanie Gentile and Ryan Montgomery led the Cooley team advising Tenet.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.